First Approval For AZ's Roxadustat With China Green Light

China is the first country to give the green light to roxadustat, AstraZeneca and FibroGen's first-in-class oral inhibitor of HIF-PHI, which could become standard of care to treat anemia in chronic kidney disease patients.

The Terracotta Army
China blazing a trail with roxadustat approval • Source: Shutterstock

AstraZeneca PLC's renal disease franchise has received a major boost with the news that partner FibroGen Inc. has bagged an approval for roxadustat to treat anemia in chronic kidney disease (CKD) patients on dialysis in China, the first country globally to approve the closely watched compound.

There is a lot of excitement surrounding roxadustat, which is a first-in-class oral inhibitor of hypoxia inducible factor-prolyl hydroxylase (HIF-PHI),...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

More from Therapeutic Category